Skip to content
Homepage
Author:
Nuvectis Pharma, Inc.
Posted Date:
June 29, 2026
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Nuvectis Pharma, Inc.
June 29, 2026
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
Nuvectis Pharma, Inc.
June 29, 2026
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Nuvectis Pharma, Inc.
June 22, 2026
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Nuvectis Pharma, Inc.
May 27, 2026
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma, Inc.
May 26, 2026
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc.
May 21, 2026
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc.
February 12, 2026
